Inflexion is pleased to announce it has agreed to sell its investment in Alcumus, a global market leader in technology-led risk management and compliance solutions to funds advised by Apax Partners LLP. The transaction values Alcumus at over £600m, generates a return of 5.9x and represents the largest-ever cash return for Inflexion following a six-year partnership which saw significant M&A and international expansion.
The announcement follows a record year of divestments by Inflexion in 2021 which included the successful sales of Halo, Medivet, Reed & Mackay and Kynetec.
Inflexion backed Cardiff-based Alcumus in late 2015 and within nine weeks completed the £47 million transformational acquisition of Santia, which significantly broadened Alcumus’ footprint in the accreditation sector. Subsequent strategic acquisitions in Canada, New Zealand and the UK enhanced Alcumus’ offering and international presence further.
These acquisitions were complemented by strong organic growth and a focus on enhancing the digital offering, which together transformed the business into a global software-based risk management solutions provider. Inflexion supported the management team to build a scalable platform providing a unified solution to its customers, improving the value proposition, and strengthening the company’s ESG offering.
Alcumus’ stellar growth is a testament to what can be achieved when a great business is led by a management team as capable as it is ambitious. It was a privilege to support their journey of international growth and transition to SaaS, and we are confident they have further to go given their strong product offering in a fast-growing, international market.
Our work together with Inflexion exceeded our already high expectations. Their expertise in M&A and international expansion together with their technology know how made a transformational difference to our business. I am extremely proud of what the team have achieved and know we remain well supported for future growth.
Contact us
Please contact us if you have any media enquiries
